### Lista potencjalnych antydepresantów ###

Posty: 1 • Strona 1 z 1

3652 / 980 / 2

### Lista potencjalnych antydepresantów ###
autor: blackgoku » 20 kwietnia 2020

Glutamatergics
NMDA receptor modulators

4-Chlorokynurenine (AV-101) – NMDA receptor glycine site antagonist
AGN-241751 – NMDA receptor modulator
Apimostinel (NRX-1074) – NMDA receptor glycine site partial agonist
Arketamine (PCN-101, HR-071603) – unknown mechanism of action, indirect AMPA receptor activator
Dextromethadone (REL-1017) – NMDA receptor antagonist open channel blocker
EVT-101 (ENS-101) – NR2B antagonist
Ketamine (Ketalar) – non-competitive NMDA receptor antagonist
Rislenemdaz (CERC-301, MK-0657) – NMDA receptor subunit 2B (NR2B) antagonist

Basimglurant (RG-7090) – mGluR5 negative allosteric modulator

Monoaminergics
Monoamine reuptake inhibitors

AN-788 (NSD-788) – serotonin–dopamine reuptake inhibitor (SDRI)
Ansofaxine (LY03005, LPM570065) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)
PDC-1421 (BLI-1005) – norepinephrine reuptake inhibitor (NRI)

Monoamine reuptake inhibitors and receptor modulators

MIN-117 (WF-516) – SDRI, 5-HT1A receptor antagonist, 5-HT2A, α1A-adrenergic, and α1B-adrenergic receptor ligand
TGBA01AD (FKB01MD) – serotonin reuptake inhibitor (SRI), 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist

Monoamine receptor modulators

Gepirone (TGFK07AD; Travivo) – 5-HT1A receptor partial agonist
Pimavanserin (Nuplazid; ACP-103; BVF-048) – 5-HT2A receptor antagonist
Psilocybin – 5-HT2A receptor partial agonist

Atypical antipsychotics

Brilaroxazine (RP-5063, RP-5000) – AA – specifically under development for the treatment of MDD and depressive episodes in bipolar disorder
Lumateperone (ITI-007) – AA – specifically under development for the treatment of depressive episodes in bipolar disorder

Others

Ademetionine (SAMe; MSI-190, MSI-195, Strada) – cofactor in monoamine neurotransmitter biosynthesis – specifically under development in the United States and Europe for the adjunctive treatment of MDD

Neurosteroids
GABAA receptor positive modulators

Ganaxolone (CCD-1042) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of postpartum depression
Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator – specifically under development for the treatment of both MDD and postpartum depression

Others
3β-Methoxypregnenolone (MAP-4343) – selective microtubule-associated protein 2 (MAP2) stimulant
PH-10 – vomeropherine (precise mechanism of action unknown/undisclosed)

Opioidergics
κ-Opioid receptor antagonists

Aticaprant (CERC-501, LY-2456302) – κ-opioid receptor antagonist
BTRX-335140 (BTRX-140) – selective k-opioid receptor antagonist
Buprenorphine/samidorphan (ALKS-5461) – κ-opioid receptor antagonist

Others
BTRX-246040 (LY-2940094) – nociceptin receptor antagonist

Others
Hydroxynorketamine ((2R,6R)-HNK) – metabolite of ketamine which may be involved in ketamine's antidepressant-like effects in mice
JNJ-39393406 – α7 nicotinic acetylcholine receptor positive allosteric modulator
JNJ-54175446 – P2RX7 purinoceptor antagonist
JNJ-61393215 – (JNJ-3215, JNJ-61393215; Orexin-1) Orexin receptor antagonists(type 1)
NNI-351 – DYRK1A inhibitor/"nerve growth factor stimulant"
NSI-189 – hippocampal neurotrophic agent (precise mechanism of action unknown)
NV-5138 – sestrin2 modulator and consequent mammalian target of rapamycin complex 1 (mTORC1) activator
OnabotulinumtoxinA (botulinum toxin A, Botox) – acetylcholine release inhibitor – specifically under development for the treatment of MDD in women as a local injection to paralyze facial muscles
Pramipexole (CTC-501, CTC-413) – Dopamine D2 and D3 receptor agonists.
Seltorexant (MIN-202, JNJ-42847922, JNJ-922) – OX2 receptor antagonist
Sirukumab (CNTO-136) – monoclonal antibody against interleukin-6
SUVN-911 – α4β2 nicotinic acetylcholine receptor antagonist or negative allosteric modulator
TS-121 – vasopressin 1B receptor antagonist

Mixed

tramadol (ETS6103; Viotra) – μ-opioid receptor agonist, serotonin–norepinephrine reuptake inhibitor (SNRI) and possible serotonin releasing agent (SRA), 5-HT2C receptor antagonist, and other actions

Combinations

bupropion/dextromethorphan (AXS-05) – σ1 receptor agonist, SNRI, non-competitive nicotinic acetylcholine receptor antagonist, uncompetitive NMDA receptor antagonist, and other actions
Cycloserine/lurasidone (NRX-101; Cyclurad) – NMDA receptor glycine site partial agonist and AA combination – specifically under development for the treatment of depressive episodes in bipolar disorder
Dextromethorphan/quinidine (AVP-786/AVP-923) – σ1 receptor agonist, SNRI, uncompetitive NMDA receptor antagonist, and other actions

Not under development

The following drugs are currently of investigational interest as potential antidepressants but are not formally under clinical development for approval at this time:

7,8-Dihydroxyflavone (7,8-DHF) – TrkB agonist
Minocycline – microglia inhibitor and other actions; a 2018 systematic review and meta-analysis reported that the overall antidepressant effect size of minocycline compared to placebo was -0.78 (95% CI: -0.4 to -1.33, P=0.005), indicative of a large and statistically significant antidepressant effect
Nitrous oxide – NMDA receptor antagonist and other actions
Pramipexole – partial or full agonist of the D2, D3, and D4 receptors
R13 – an orally active prodrug of 7,8-DHF with improved pharmacokinetics
LSD

Publikacje:

Spoiler:

References

"AV 101". adisinsight.springer.com. Retrieved 7 May 2017.
"AGN-241751 - Allergan". adisinsight.springer.com. Retrieved 28 August 2018.
"Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration". www.prnewswire.com. Retrieved 28 August 2018.
"Apimostinel". adisinsight.springer.com. Retrieved 7 May 2017.
Hashimoto, Kenji (2019). "Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective". Psychiatry and Clinical Neurosciences. 73 (10): 613–627. DOI:10.1111/pcn.12902. ISSN 1323-1316. PMC 6851782. PMID 31215725.
https://adisinsight.springer.com/drugs/800056158
"Dextromethadone - Relmada Therapeutics". adisinsight.springer.com. Retrieved 10 November 2018.
"EVT 101". adisinsight.springer.com. Retrieved 7 May 2017.
"Ketamine intranasal - Vyera Pharmaceuticals". adisinsight.springer.com. Retrieved 7 May 2017.
"CERC 301". adisinsight.springer.com. Retrieved 7 May 2017.
"Basimglurant". adisinsight.springer.com. Retrieved 7 May 2017.
Machado-Vieira R, Henter ID, Zarate CA (May 2017). "New targets for rapid antidepressant action". Progress in Neurobiology. 152: 21–37. DOI:10.1016/j.pneurobio.2015.12.001. PMC 4919246. PMID 26724279.
Lener MS, Kadriu B, Zarate CA (March 2017). "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression". Drugs. 77 (4): 381–401. DOI:10.1007/s40265-017-0702-8. PMC 5342919. PMID 28194724.
"AN 788". adisinsight.springer.com. Retrieved 7 May 2017.
"LY 03005". adisinsight.springer.com. Retrieved 7 May 2017.
"PDC-1421". adisinsight.springer.com. Retrieved 24 March 2018.
"MIN 117". adisinsight.springer.com. Retrieved 7 May 2017.
"FKB 01MD". adisinsight.springer.com. Retrieved 7 May 2017.
"Gepirone ER". adisinsight.springer.com. Retrieved 7 May 2017.
"Pimavanserin". adisinsight.springer.com. Retrieved 25 September 2017.
"Psilocybin". adisinsight.springer.com. Retrieved 26 October 2018.
"RP 5063". adisinsight.springer.com. Retrieved 7 May 2017.
"Lumateperone". adisinsight.springer.com. Retrieved 7 May 2017.
"Ademetionine". adisinsight.springer.com. Retrieved 7 May 2017.
"Ganaxolone". adisinsight.springer.com. Retrieved 24 March 2018.
"SAGE 217". adisinsight.springer.com. Retrieved 9 February 2018.
"Pregnenolone methyl ether". adisinsight.springer.com. Retrieved 7 May 2017.
"PH 10 nasal spray". adisinsight.springer.com. Retrieved 7 May 2017.
"Aticaprant". adisinsight.springer.com. Retrieved 11 November 2019.
"BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Retrieved 2020-01-25.
"BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
"Buprenorphine/samidorphan". adisinsight.springer.com. Retrieved 7 May 2017.
"BTRX-246040". adisinsight.springer.com. Retrieved 24 March 2018.
Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. (May 2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533 (7604): 481–6. DOI:10.1038/nature17998. PMC 4922311. PMID 27144355. Lay summary – ScienceDaily.
"JNJ 39393406". adisinsight.springer.com. Retrieved 7 May 2017.
"JNJ-54175446". adisinsight.springer.com. Retrieved 24 March 2018.
"JNJ 61393215 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
"A Study of JNJ-61393215 in the Treatment of Depression - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-01-25.
"Research programme: psychiatric and neurological disorders therapeutics - Neuronascent". adisinsight.springer.com. Retrieved 7 May 2017.
"NSI 189". adisinsight.springer.com. Retrieved 7 May 2017.
"NV 5138". adisinsight.springer.com. Retrieved 7 November 2018.
Duman RS (2018). "Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide". F1000Research. 7: 659. DOI:10.12688/f1000research.14344.1. PMC 5968361. PMID 29899972.
Duman R, Kato T, Liu RJ, Duman C, Terwilliger R, Vlasuk G, Hahm S, Sajah E (November 2017). "Sestrin 2 Modulator NV-5138 Shows Ketamine-Like Rapid Antidepressant Effects via Direct Activation of mTORC1 Signaling" (PDF). Neuropsychopharmacology. 43: S195.
"Botulinum toxin A injectable - Allergan". adisinsight.springer.com. Retrieved 7 May 2017.
"Product Discovery and Development". Chase Therapeutics. Retrieved 2020-01-25.
"Pramipexole - Chase Therapeutics - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
"JNJ 42847922". adisinsight.springer.com. Retrieved 7 May 2017.
"Sirukumab". adisinsight.springer.com. Retrieved 7 May 2017.
"SUVN-911". adisinsight.springer.com. Retrieved 24 March 2018.
"TS 121". adisinsight.springer.com. Retrieved 7 May 2017.
"tramadol controlled release - e-Therapeutics". adisinsight.springer.com. Retrieved 7 May 2017.
"Another depression drug flops as e-Therapeutics tallies PhIIb data - FierceBiotech". www.fiercebiotech.com. Retrieved 28 August 2018.
"E-Therapeutics defends PhIIb fail, claiming drug has 'pretty much' the hoped-for profile - FierceBiotech". www.fiercebiotech.com. Retrieved 28 August 2018.
"bupropion/dextromethorphan - Axsome Therapeutics". adisinsight.springer.com. Retrieved 7 May 2017.
"Cycloserine/lurasidone - NeuroRx". adisinsight.springer.com. Retrieved 7 May 2017.
"Deudextromethorphan". adisinsight.springer.com. Retrieved 7 May 2017.
Zeng Y, Wang X, Wang Q, Liu S, Hu X, McClintock SM (November 2013). "Small molecules activating TrkB receptor for treating a variety of CNS disorders". CNS &AMP; Neurological Disorders Drug Targets. 12 (7): 1066–77. DOI:10.2174/18715273113129990089. PMID 23844685.
Zhang JC, Yao W, Hashimoto K (2016). "Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets". Current Neuropharmacology. 14 (7): 721–31. DOI:10.2174/1570159X14666160119094646. PMC 5050398. PMID 26786147.
Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration. 5: 2. DOI:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.
Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, Phun LH, France S, Xiao G, Jia Y, Luo HR, Ye K (December 2010). "A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect". Journal of Medicinal Chemistry. 53 (23): 8274–86. DOI:10.1021/jm101206p. PMC 3150605. PMID 21073191.
Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (October 2014). "Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation". The International Journal of Neuropsychopharmacology. 18 (4). DOI:10.1093/ijnp/pyu077. PMC 4360225. PMID 25628381.
Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (December 2015). "Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression". Psychopharmacology. 232 (23): 4325–35. DOI:10.1007/s00213-015-4062-3. PMID 26337614.
Chang HA, Wang YH, Tung CS, Yeh CB, Liu YP (September 2016). "7,8-Dihydroxyflavone, a Tropomyosin-Kinase Related Receptor B Agonist, Produces Fast-Onset Antidepressant-Like Effects in Rats Exposed to Chronic Mild Stress". Psychiatry Investigation. 13 (5): 531–540. DOI:10.4306/pi.2016.13.5.531. PMC 5067348. PMID 27757132.
Zhang MW, Zhang SF, Li ZH, Han F (December 2016). "7,8-Dihydroxyflavone reverses the depressive symptoms in mouse chronic mild stress". Neuroscience Letters. 635: 33–38. DOI:10.1016/j.neulet.2016.10.035. PMID 27773794.
Rosenblat JD, McIntyre RS (February 2018). "Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials". Journal of Affective Disorders. 227: 219–225. DOI:10.1016/j.jad.2017.10.042. PMID 29102836.
Cohen IV, Makunts T, Atayee R, Abagyan R (May 2017). "Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications". Scientific Reports. 7 (1): 1450. DOI:10.1038/s41598-017-01590-x. PMC 5431207. PMID 28469132.
Nagele P, Zorumski CF, Conway C (April 2018). "Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts". Journal of Clinical Psychopharmacology. 38 (2): 144–148. DOI:10.1097/JCP.0000000000000837. PMC 5825282. PMID 29360650.
Zorumski CF, Nagele P, Mennerick S, Conway CR (2015). "Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy". Frontiers in Psychiatry. 6: 172. DOI:10.3389/fpsyt.2015.00172. PMC 4673867. PMID 26696909.
Harrison, Pam (April 7, 2016). "Parkinson's Drug Highly Effective for Resistant Depression". www.medscape.com. WebMD. Retrieved 2018-02-12.
Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 115 (3): 578–583. DOI:10.1073/pnas.1718683115. PMC 5777001. PMID 29295929.
Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE (June 2016). "Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years". Therapeutic Advances in Psychopharmacology. 6 (3): 193–213. DOI:10.1177/2045125316638008. PMC 4910400. PMID 27354908.

Gdy możesz być kim chcesz. Bądź sobą. No chyba, że możesz być Son Goku, wtedy zawsze bądź Son Goku.
Posiąść wszelką wiedzę leży w zasięgu możliwości człowieka ~ Leonardo da Vinci
Szukaj mnie na: https://pubmed.ncbi.nlm.nih.gov/

ODPOWIEDZ

Posty: 1 • Strona 1 z 1

NarkoMemy dodaj swój

Dziś detox 😁

HyperTuba dodaj film

LSD Trip Simulation Replication [Accurate POV]

Artykuły

Opisała życie w Norwegii. "Narkotyki są tanie, a państwo opiekuńcze"

Marta Hopfer-Gilles mieszka w stolicy Norwegii od 7 lat. W swojej książce pisze wprost, że w Oslo czuje się bezpiecznie, choć doskonale zdaje sobie sprawę z ciemnej strony miasta. Oslo chce być barwne, otwarte, nowoczesne i wielokulturowe, ale widać w nim też biedę, nierówność społeczną, narkotyki i brutalną przestępczość.

sobota, 29. Październik 2022 - 13:30

Marihuana i epilepsja

W ostatnich latach leki na bazie konopi stały się alternatywą dla różnych leków konwencjonalnych. Wydaje się, że najlepiej udało się to w przypadku leków przeciwpadaczkowych. Leki zawierające CBD okazały się lepsze w wielu przypadkach padaczki, zwłaszcza w jej ciężkich formach, takich jak zespół Dravet czy zespół Lennoxa-Gastauta.

czwartek, 22. Grudzień 2022 - 11:30

Najsilniejsza odmiana marihuany na świecie 2022

Marihuana z roku na rok jest coraz silniejsza. Zjawisko to bada m.in. Amerykański Krajowy Instytut ds. Nadużywania Narkotyków (National Institute on Drug Abuse – NIDA), analizując próbki konfiskowanej marihuany. Na ich podstawie co roku publikuje dane statystyczne – w tym o trendzie zawartości THC. Obserwowany wzrost mocy jest tak duży, że wręcz ciężko w niego uwierzyć. Według statystyk w 1978 roku przeciętna próbka marihuany zawierała mniej niż 1% THC! Obecnie nietrudno dostać taką, która zawiera blisko 30%.

piątek, 7. Październik 2022 - 14:00

Newsy

Jacht z kokainą o wartości 80 milionów funtów zmierzał w stronę Wielkiej Brytanii

Prawie tona „narkotyku klasy A” została znaleziona na jachcie płynącym z wysp karaibskich do Wielkiej Brytanii. Jej rynkowa wartość została oszacowana na 80 milionów funtów.

wtorek, 29. Czerwiec 2021 - 8:50

Handel narkotykami: Rynek odporny na COVID-19. Coraz większe obroty w internecie

Dynamika rynku handlu narkotykami po krótkim spadku w początkowym okresie pandemii COVID-19 szybko dostosowała się do nowych realiów, wynika z opublikowanego w czwartek (24 czerwca) przez Biuro Narodów Zjednoczonych ds. Narkotyków i Przestępczości (UNODC) nowego Światowego Raportu o Narkotykach.

sobota, 26. Czerwiec 2021 - 10:30

Meksyk: Sąd Najwyższy zdepenalizował rekreacyjne spożycie marihuany

Sąd Najwyższy zdepenalizował w poniedziałek rekreacyjne spożycie marihuany przez dorosłych. Za zalegalizowaniem używki głosowało 8 spośród 11 sędziów. SN po raz kolejny zajął się tą sprawą, jako że Kongres nie zdołał przyjąć stosownej ustawy przed 30 kwietnia.

wtorek, 29. Czerwiec 2021 - 9:10

TALK - Rozmowy [H]

Załóż u nas konto!

Zachowaj bezpieczeństwo

Dlaczego warto mieć konto?

Przestrzegaj regulaminu

Zgłoś naruszenie regulaminu